Compare iShares MSCI Malaysia ETF (EWM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Sanofi SA — how do they compare? iShares MSCI Malaysia ETF trades at $26.66 (market cap $256.41M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 371.2× iShares MSCI Malaysia ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and Sanofi SA for 94 Days on average.
| EWM | SNY | |
|---|---|---|
Market Cap | $256.41M | $95.18B |
Volume | 111,962 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $52.34 |
52-Week Low | $25.33 | $39.51 |
Typical Hold Time | 66 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM stock trades at $26.66 with minimal daily movement (+0.19%). Technical indicators show conflicting signals with moving averages suggesting bearish pressure while oscillators indicate potential oversold conditions. The stock faces immediate resistance at $27 and support at $26. Recent news highlights regional environmental challenges affecting operations.
The stock presents a cautious outlook with mixed technical signals and limited fundamental data available. Near-term direction will depend on earnings results and management guidance. Key risks include operational disruptions from regional environmental issues and broader market volatility affecting small-cap stocks.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
